Sacituzumab Govitecan for Injection 戈沙妥珠单抗注射液

‌Gosatuzumab‌ is an antibody-drug conjugate (ADC) targeting TROP-2. It binds to the TROP-2 protein on the surface of tumor cells and releases chemotherapy drugs in a targeted manner. It is used to treat specific advanced solid tumors such as triple-negative breast cancer and urothelial carcinoma. Its core mechanism is to kill cancer cells precisely while reducing damage to normal tissues.

Mechanism of action and characteristics
Gosatuzumab consists of two parts: an antibody part and a cytotoxic drug:

The antibody part recognizes and binds to the TROP-2 protein (an antigen highly expressed in many solid tumors) on the surface of cancer cells.
The cytotoxic drug (SN-38) binds to the antibody through a linker, enters the cancer cell and is released, inhibiting DNA replication and causing cell apoptosis.
This design achieves the targeted delivery of chemotherapy drugs, improving efficacy while reducing systemic toxicity.
Indications and clinical applications
Currently, gosartan is mainly used for:

‌Triple-negative breast cancer (TNBC): For advanced patients who have received at least two systemic treatments, it can prolong progression-free survival (PFS) and overall survival (OS).
‌Urothelial carcinoma‌: Suitable for patients with locally advanced or metastatic disease who have failed or cannot tolerate platinum-containing chemotherapy.
In addition, the study of this drug in other TROP-2 high-expressing tumors (such as non-small cell lung cancer and ovarian cancer) is ongoing.
Efficacy and safety
‌Efficacy‌: In the Phase III clinical trial of triple-negative breast cancer, the median overall survival of the gosartan group was 11.8 months, significantly better than the 6.9 months of the chemotherapy group.
‌Common side effects‌: Including neutropenia, diarrhea, nausea, hair loss, etc., most of which are mild to moderate.
‌Serious risks‌: Be alert to bone marrow suppression (such as severe neutropenia) and hypersensitivity reactions, and regular monitoring of blood routine and liver and kidney function is required.
Precautions for use
Contraindications: Contraindicated for those who are allergic to the drug ingredients; treatment should be delayed for those with severe bone marrow suppression or active infection.
Special populations: Pregnant women, lactating women, and those with impaired liver and kidney function need to carefully assess the risks.
Treatment management: It is recommended to use anti-emetic drugs prophylactically before taking the drug, and adjust the dose according to adverse reactions.
Research progress and future directions
Combination therapy with gosartuzumab (such as with immune checkpoint inhibitors) is being explored and may further expand indications. In addition, the development of various ADC drugs for TROP-2 is progressing rapidly, which may promote the development of personalized treatment in the future.
Gosartuzumab represents an important breakthrough in the targeted treatment of solid tumors, but its application must strictly follow the indications and be individually evaluated under the guidance of professional doctors.
See more